Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells

[1]  P. Scheurich,et al.  Inhibition of Death Receptor-mediated Gene Induction by a Cycloheximide-sensitive Factor Occurs at the Level of or Upstream of Fas-associated Death Domain Protein (FADD)* , 2000, The Journal of Biological Chemistry.

[2]  S. Fulda,et al.  Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. , 2000, Cancer research.

[3]  M. Peter,et al.  Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. , 2000, Blood.

[4]  P. Koistinen,et al.  Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells. , 2000, Leukemia research.

[5]  A. Strasser,et al.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Tomonaga,et al.  Fas-resistance in ATL cell lines not associated with HTLV-I or FAP-1 production. , 1999, Cancer letters.

[7]  S. Im,et al.  Distinct patterns of apoptosis in association with modulation of CD44 induced by thrombopoietin and granulocyte‐colony stimulating factor during ex vivo expansion of human cord blood CD34+ cells , 1999, British journal of haematology.

[8]  S. Chi,et al.  TGF-β1 inhibition of apoptosis through the transcriptional up-regulation of Bcl-X(L) in human monocytic leukemia U937 cells , 1999, Experimental & Molecular Medicine.

[9]  S. Ugurel,et al.  Heterogenous susceptibility to CD95‐induced apoptosis in melanoma cells correlates with bcl‐2 and bcl‐x expression and is sensitive to modulation by interferon‐γ , 1999, International journal of cancer.

[10]  G. Schackert,et al.  Expression ofTRAILand Its Receptors in Human Brain Tumors , 1999 .

[11]  C. Smith,et al.  Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.

[12]  K. Bhatia,et al.  Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. , 1999, Cancer research.

[13]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[14]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[15]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[16]  E. Krebs,et al.  A comparison of signaling requirements for apoptosis of human B lymphocytes induced by the B cell receptor and CD95/Fas. , 1998, Journal of immunology.

[17]  D. Ferrari,et al.  Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.

[18]  H. Kalthoff,et al.  Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. , 1998, Cancer research.

[19]  P. Möller,et al.  Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. , 1998, Cancer research.

[20]  J. Houghton,et al.  The fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Shigeki Tanaka,et al.  mRNA expression of Fas receptor (CD95)‐associated proteins (Fas‐associated phosphatase‐1/FAP‐1, Fas‐associating protein with death domain/FADD, and receptor‐interacting protein/RIP) in human leukaemia/lymphoma cell lines , 1997, British journal of haematology.

[22]  V. Depraetere,et al.  Fas and other cell death signaling pathways. , 1997, Seminars in immunology.

[23]  E. Russell,et al.  Fas expression and function in normal and malignant breast cell lines. , 1996, Cancer research.

[24]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[25]  M. Kojiro,et al.  Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. , 1996, The American journal of pathology.

[26]  G. Natoli,et al.  Resistance to Fas-mediated apoptosis in human hepatoma cells. , 1995, Oncogene.

[27]  S. Orrenius,et al.  Cellular events in Fas/APO-1-mediated apoptosis in JURKAT T lymphocytes. , 1995, Experimental cell research.

[28]  John Calvin Reed,et al.  FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.

[29]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[30]  S. Korsmeyer.  Regulators of cell death. , 1995, Trends in genetics : TIG.

[31]  J. Inazawa,et al.  Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.

[32]  M. Weller,et al.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. , 1994, The Journal of clinical investigation.

[33]  K. Koretz,et al.  Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.

[34]  I Schmid,et al.  A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. , 1994, Journal of immunological methods.

[35]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[36]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[37]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[38]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[39]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Hamada,et al.  Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Schackert,et al.  Expression of TRAIL and its receptors in human brain tumors. , 1999, Biochemical and biophysical research communications.

[42]  P. Krammer,et al.  Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. , 1995, Leukemia.

[43]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.